HealthcareBiomanufacturing
Samsung Biologics
삼성바이오로직스
World-leading CDMO for biologics manufacturing.
Ticker
KRX 207940
CEO
John Rim
Employees
5,000
Founded
2011
Last update
Nov 05, 2026, 08:21 AM GMT-3
Latest News
Healthcare
Samsung Biologics Achieves Top ESG Rating, Ranking 4th Globally
Samsung Biologics has received a top-tier rating in Sustainalytics' ESG assessment, ranking 4th globally.

Healthcare
Samsung Biologics Secures Top ESG Rating From Morningstar Sustainalytics
Samsung Biologics has achieved a 'Negligible Risk' ESG rating from Morningstar Sustainalytics, highlighting its commitment to sustainability.

Healthcare
Samsung Biologics Achieves 'Negligible Risk' Rating in ESG Assessment
Samsung Biologics has received a 'Negligible Risk' rating from Sustainalytics, showcasing its commitment to ESG standards.
Healthcare
Samsung Biologics Secures $323M Contract Amid Biosecure Act Changes
Samsung Biologics has landed a $323 million contract for biologics manufacturing, leveraging the US Biosecure Act.
Timeline
Related companies
Koreabw · Samsung Biologics